Deslanoside (Cedilanid-D)

Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.

Also Known As:

Cedilanid-D; Desacetyl Lanatoside; Deslanatoside C; Cedilanid D; CedilanidD; Lanatoside, Desacetyl; Desacetyldigilanide C; Desacetyllanatoside C; Card-20(22)-enolide, 3-((O-beta-D-glucopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)-

Networked: 42 relevant articles (0 outcomes, 0 trials/studies)

Drug Context: Research Results

Experts

1.	A, Jun: 1 article (11/2021)
2.	Dong, Jin-Tang: 1 article (11/2021)
3.	Huang, Qingqing: 1 article (11/2021)
4.	Li, Linyue: 1 article (11/2021)
5.	Li, Xiawei: 1 article (11/2021)
6.	Liu, Mingcheng: 1 article (11/2021)
7.	Zhang, Zhiqian: 1 article (11/2021)
8.	Cao, Yuying: 1 article (10/2017)
9.	He, Yongqun: 1 article (10/2017)
10.	Li, Mei: 1 article (10/2017)

Related Diseases

1.	Cardiac Arrhythmias (Arrythmia) 11/01/1982 - "These results are consistent with the hypothesis that the increased resistance to arrhythmia induced by desacetyl lanatoside C in decorticated rats is mediated by the posterior hypothalamus." 11/01/1982 - "To examine the role of the posterior hypothalamus in the increased resistance of decorticated rats to arrhythmia induced by toxic doses of desacetyl lanatoside C, four groups of animals were injected with this drug: group 1 rats had a craniotomy; group 2 rats had a craniotomy and functional decortication; group 3 rats had a craniotomy and a hypothalamic lesion; and group 4 rats had a craniotomy, hypothalamic lesion and functional decortication. " 12/01/1971 - "Effects of beta-adrenoreceptor blocking agents on the deslanoside-induced arrhythmia and cardiac arrest in guinea pigs." 10/31/2012 - "Ethanol (0.4, 0.8 and 1.6 g/kg) consumption remarkably increased the cumulative dosage of deslanoside to induce ventricualr premature contraction (P < 0.01) on deslanoside-induced arrhythmia in guinea pigs. " 02/15/1978 - "In addition, methysergide administered in the above doses to cats intoxicated with deslanoside, restored an abnormal ventricular arrhythmia to either sinus or junctional rhythm. "
2.	Ventricular Fibrillation 11/01/1983 - "However, this dose of deslanoside caused ventricular fibrillation in all 6 experiments. " 11/01/1982 - "Functional ablation of the cerebral cortex by cortical spreading depression (CSD) significantly increased the dose of desacetyl lanatoside C required to induce A-V block and ventricular fibrillation. " 11/01/1979 - "Experiments were performed in cats and arterial blood samples were taken prior to initiating deslanoside infusion and at the point when it appeared from the ECG that ventricular fibrillation was imminent. " 11/01/1978 - "This was investigated by intoxicating anesthetized cats with deslanoside, removing cardiac and brain tissue at the onset of ventricular fibrillation, and examining the ability of brain tissue to accumulate [3H]-NE, [3H]-T-HT and [3H]-DA and cardiac tissue to accumulate [3H]-NE. " 10/01/1975 - "When deslanoside was given to control animals, 150 +/- 8.2 and 179 +/- 11.9 mug/kg produced ventricular tachycardia and ventricular fibrillation, respectively. "
3.	Heart Failure 07/01/1989 - "In the heart failure patients, Cedilanid-D significantly increased systolic and pulse pressures, whereas mean arterial pressure was unchanged. " 10/01/1979 - "The effect of pentaformilgitoxin and deslanoside on heart rate, blood pressure and cardiac output was compared in six patients with heart failure. " 10/01/1979 - "Comparison of hemodynamic effects induced by pentaformilgitoxin and deslanoside in patients with heart failure." 07/01/1989 - "To determine whether or not these contrasting vascular responses are due to differing autonomic actions of the drug, we compared the responses to intravenous administration of Cedilanid-D (0.02 mg/kg) in eight normal subjects (mean age, 23 +/- 1 years) and eight patients with moderate-to-severe heart failure (mean age, 52 +/- 5 years, NYHA Class III-IV). " 06/01/1965 - "[DESACETYL-LANATOSIDE C IN THERAPY OF HEART DECOMPENSATION]."
4.	Heart Diseases (Heart Disease) 10/01/1965 - "[Desacetyl-lanatoside-C in heart diseases]." 09/15/1965 - "[Experiences with desacetyl-lanatoside C in treatment and in preparation for surgery of surgical heart disease patients]." 09/01/1963 - "[THE TREATMENT OF DECOMPENSATED HEART DISEASES WITH A NEW DIGITALIC DRUG (DESACETYLLANATOSIDE C)]." 09/15/1965 - "[On the use of desacetyl-lanatoside C in therapy of uncompensated heart diseases. "
5.	Cardiotoxicity 11/01/1979 - "This increase in free serotonin in plasma caused by inhibition of uptake may play a role in the cardiotoxicity of deslanoside." 10/01/1975 - "These results indicate that blockade of both nicotinic and muscarinic ganglionic transmission is essential for a protective influence against cardiotoxicity induced by deslanoside." 10/01/1975 - "The effect of ganglionic blockade on cardiotoxicity induced by deslanoside (25 mug/kg i.v. at 15-minute intervals) was evaluated in Dial-urethane anesthetized cats. " 10/01/1975 - "Antagonism of deslanoside-induced cardiotoxicity by combined nicotinic and muscarinic blockade of autonomic ganglia." 03/01/1973 - "The suppressive activities of alprenolol against deslanoside-induced cardiotoxicities in guinea pigs."

Related Drugs and Biologics

1.	Picrotoxin
2.	Pentylenetetrazole (Metrazol)
3.	Hexamethonium (Hexamethonium Bromide)
4.	Serotonin (5 Hydroxytryptamine)
5.	Digoxin (Digitek)
6.	Deslanoside (Cedilanid-D)
7.	Alprenolol
8.	Hyoscyamine
9.	Therapeutic Uses
10.	Tetraethylammonium (Tetraethylammonium Bromide)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Administration
3.	Artificial Respiration (Mechanical Ventilation)
4.	Intravenous Injections
5.	Injections